A high-throughput platform identifies novel drug combinations towards acute myeloid leukemia therapy

被引：0
|
作者：
Soltis, Anthony R.
Zhelyazkova, Boryana
Drane, Pascal
Eleftheriadis, Efstathios
Ventresco, Andrew
Weitz, David A.
Lee, Arlinda
Iafrate, Anthony J.
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-3900
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A3900
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Phenotypic high-throughput screening platform identifies novel chemotypes for necroptosis inhibition
    Brito, Hugo
    Marques, Vanda
    Afonso, Marta B.
    Brown, Dean G.
    Borjesson, Ulf
    Selmi, Nidhal
    Smith, David M.
    Roberts, Ieuan O.
    Fitzek, Martina
    Aniceto, Natalia
    Guedes, Rita C.
    Moreira, Rui
    Rodrigues, Cecilia M. P.
    CELL DEATH DISCOVERY, 2020, 6 (01)
  • [22] A function-based high-throughput discovery platform, myeloid iOTarg, identifies novel immune checkpoints of the tumor microenvironment
    Sudan, Kritika
    Michels, Tillmann
    Amerhauser, Carmen
    Tschulik, Claudia
    Majunke, Leonie
    Albert, Lucille
    Volpin, Valentina
    Turqueti-Neves, Adriana
    Milde, Ronny
    Khandelwal, Nisit
    CANCER RESEARCH, 2023, 83 (07)
  • [23] Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing
    Pietarinen, P. O.
    Pemovska, T.
    Kontro, M.
    Yadav, B.
    Mpindi, J. P.
    Andersson, E. I.
    Majumder, M. M.
    Kuusanmaki, H.
    Koskenvesa, P.
    Kallioniemi, O.
    Wennerberg, K.
    Heckman, C. A.
    Mustjoki, S.
    Porkka, K.
    BLOOD CANCER JOURNAL, 2015, 5
  • [24] Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing
    P O Pietarinen
    T Pemovska
    M Kontro
    B Yadav
    J P Mpindi
    E I Andersson
    M M Majumder
    H Kuusanmäki
    P Koskenvesa
    O Kallioniemi
    K Wennerberg
    C A Heckman
    S Mustjoki
    K Porkka
    Blood Cancer Journal, 2015, 5 (5) : e309 - e309
  • [25] OUTCOME OF PERSONALIZED THERAPY BASED ON HIGH-THROUGHPUT EX VIVO DRUG SCREENING IN PATIENTS WITH RELAPSED, CHEMOREFRACTORY ACUTE MYELOID LEUKEMIA (AML)
    Kontro, M.
    Pemovska, Tea
    Kulesskiy, E.
    Edgren, H.
    Eldfors, S.
    Elonen, E.
    Karjalainen, R.
    Majumder, M.
    Murumagi, A.
    Parsons, A.
    Aittokallio, T.
    Wennerberg, K.
    Kallioniemi, O.
    Porkka, K.
    HAEMATOLOGICA, 2013, 98 : 19 - 20
  • [26] Niche-like Ex Vivo High Throughput (NEXT) Drug Screening Platform in Acute Myeloid Leukemia
    Figueiras, Reinaldo Dal Bello
    Pasanisi, Justine
    Joudinaud, Romane
    Duchmann, Matthieu
    Sodaro, Gaetano
    Chauvel, Clementine
    Vasseur, Loic
    Pardieu, Bryann
    Ling, Frank
    Pacchiardi, Kim
    Vaganay, Camille
    Faivre, Lionel
    Benaksas, Chaima
    Preudhomme, Claude
    Raffoux, Emmanuel
    Clappier, Emmanuelle
    Ades, Lionel
    Puissant, Alexandre
    Itzykson, Raphael
    BLOOD, 2020, 136
  • [27] Associating Ex Vivo Drug Sensitivity with Differentiation Status Identifies Effective Drug Combinations for Acute Myeloid Leukemia
    Eide, Christopher A.
    Kurtz, Stephen E.
    Kaempf, Andy
    Long, Nicola
    Bottomly, Daniel
    Nikolova, Olga
    Druker, Brian J.
    McWeeney, Shannon K.
    Tyner, Jeffrey W.
    Agarwal, Anupriya
    BLOOD, 2021, 138
  • [28] High-Throughput Matrix Synergy Screening Identifies Novel Therapeutic Combinations for Merkel Cell Carcinoma
    Garman, Khalid
    Gelb, Tara
    Urban, Daniel
    Hall, Matthew
    Brownell, Isaac
    FASEB JOURNAL, 2020, 34
  • [29] Novel Therapeutics Targeting Acute Myeloid Leukemia (AML) Stem Cells Identified through High-Throughput Screening
    Iasenza, Isabella
    Safa, Safia
    Barabe, Frederic
    Cellot, Sonia
    Wilhelm, Brian T.
    Eppert, Kolja
    BLOOD, 2023, 142
  • [30] Drug therapy for acute myeloid leukemia
    Tallman, MS
    Gilliland, DG
    Rowe, JM
    BLOOD, 2005, 106 (04) : 1154 - 1163
12345